The study proposes mitigation measures and policy options to minimise these risks and maximise the benefits of medical AI, including multi-stakeholder engagement through the AI production lifetime, increased transparency and traceability, in-depth clinical validation of AI tools, and AI training and education for both clinicians and citizens.
